(Q36715888)

15 August 2017

1 reference

title

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? (English)

1 reference

15 August 2017

0 references

Buckley PF

1

1 reference

PubMed ID

17244172

15 August 2017

Stahl SM

series ordinal

2

1 reference

PubMed ID

17244172

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Acta Psychiatrica Scandinavica

15 August 2017

1 reference

15 August 2017

115

1 reference

15 August 2017

2

1 reference

15 August 2017

93-100

1 reference

Treatment of schizophrenia negative symptoms: future prospects

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Negative symptoms of schizophrenia: a problem that will not go away

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

An industry perspective on the NIMH consensus statement on negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

The NIMH-MATRICS consensus statement on negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Negative symptoms in schizophrenia: comments from a clinical psychology perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Structural evaluation of the prefrontal cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Maintenance treatment for schizophrenia with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

A successful antipsychotic combination trial. Quo Vadis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Management of the negative symptoms of schizophrenia: new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Evidence-based psychotherapy for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Cognitive behavior therapy for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Focus on polypharmacy in schizophrenia: does anyone truly benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Patient response and resource management: another view of clozapine treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2007.00992.X

10.1111/J.1600-0447.2007.00992.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17244172